Welcome to the international HTA database

Showing [21894 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2019	Health Technology Wales (HTW)	Pharmacogenetic testing to identify the risk of adverse reactions to anti-epileptic medications
2019	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Mexiletine]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Nintedanib (idiopathic pulmonary fibrosis) - Addendum to Commission A19-36]
2019	Health Quality Ontario (HQO)	Internet-Delivered Cognitive Behavioural Therapy for Major Depression and Anxiety Disorders: A Health Technology Assessment
2019	NIHR Health Services and Delivery Research programme	Innovation to enhance health in care homes: rapid evidence synthesis
2019	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Assessment and interventions in care and services for older adults - an evidence map]
2019	Ontario Health	Osseointegrated Prosthetic Implants for People With Lower-Limb Amputation: A Health Technology Assessment
2019	Health Technology Wales (HTW)	Occipital nerve stimulation for medically refractory chronic cluster headache
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pegvaliase (phenylketonuria) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2019	Health Sciences Institute in Aragon (IACS)	Efficacy, effectiveness and safety of intraoperative radiotherapy in breast carcinoma
2019	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Pegvaliase]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Dapagliflozin/metformin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V]
2019	NIHR Health Technology Assessment programme	The Effectiveness and cost-effectiveness of Surgical Treatments for womEn with stRess urinary incontinence: an evidence synthesis (ESTER)
2019	Health Sciences Institute in Aragon (IACS)	Detection of diabetes' complications. Diabetic retinopathy. Economic evaluation of ultra-wide field scanning laser
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Dapagliflozin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Dapagliflozin (type 1 diabetes mellitus) - Addendum to Commission A19-37]
2019	European Network for Health Technology Assessment (EUnetHTA)	Stool DNA testing for early detection of colorectal cancer
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Data-supported timely management in cooperation with a centre for telemedicine for patients with advanced cardiac failure - rapid report]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Relationship between volume of services and quality of treatment outcome for lung cancer - rapid report]
2019	Ontario Health	Flash Glucose Monitoring System for People with Type 1 or Type 2 Diabetes: A Health Technology Assessment
2019	European Network for Health Technology Assessment (EUnetHTA)	C-reactive protein point-of-care testing (CRP POCT) to guide antibiotic prescribing in primary care settings for acute respiratory tract infections (RTIs)
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Olaparib (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2019	European Network for Health Technology Assessment (EUnetHTA)	Robot-assisted surgery in thoracic and visceral indications
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Olaparib (ovarian cancer) - Benefit assessment according to §35a Social Code Book V]
2019	NIHR Public Health Research (PHR) programme	NAP SACC UK: a feasibility cluster randomised controlled trial in child care settings to increase physical activity and healthy eating in 2-4 year olds
2019	European Network for Health Technology Assessment (EUnetHTA)	Irreversible electroporation for the treatment of liver and pancreatic cancer
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Fremanezumab (migraine) - Addendum to Commission A19-44]
2019	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Chondroitin sulfate in osteoarthritis
2019	Ontario Health	Minimally Invasive Glaucoma Surgery: A Budget Impact Analysis and Evaluation of Patients’ Experiences, Preferences, and Values
2019	European Network for Health Technology Assessment (EUnetHTA)	Bioresorbable stents for the treatment of cardiovascular indications (coronary artery disease)
2019	The Federal Joint Committee (G-BA)	Pharmaceutical Directive/Annex XII: Voretigene Neparvovec
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Risankizumab (plaque psoriasis) - Second Addendum to Commission A19-41]
2019	NIHR Health Technology Assessment programme	Behavioural Activation Therapy for Depression after Stroke (BEADS): a feasibility randomised controlled pilot trial of a psychological intervention for post-stroke depression
2019	European Network for Health Technology Assessment (EUnetHTA)	Lithium triborate (LBO) laser for photoselective vaporisation of the prostate (PVP) in the treatment of benign prostatic hyperplasia (BPH)
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Turoctocog alfa pegol - Benefit assessment according to §35a Social Code Book V]
2019	NIHR Health Technology Assessment programme	A group memory rehabilitation programme for people with traumatic brain injuries: the ReMemBrIn RCT
2019	NIHR Public Health Research (PHR) programme	Adapting a falls prevention exercise programme with and for older people with visual impairment: a feasibility study
2019	European Network for Health Technology Assessment (EUnetHTA)	Regional hyperthermia for high-risk soft tissue sarcoma treatment
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Dolutegravir/lamivudine (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2019	Belgian Health Care Knowledge Centre (KCE)	Polyvalent immunoglobulins – Part 1: A rapid review
2019	European Network for Health Technology Assessment (EUnetHTA)	Screening for osteoporosis in the general population
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Cemiplimab - Benefit assessment according to §35a Social Code Book V]
2019	European Network for Health Technology Assessment (EUnetHTA)	Prophylactic or therapeutic use of endoanchoring systems in endovascular aortic aneurysm repair (EVAR/TEVAR)
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ravulizumab - Benefit assessment according to §35a Social Code Book V]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Risankizumab (plaque psoriasis) - Addendum to Commission A19-41]
2019	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Human dermal allograft for massive rotator cuff tears
2019	NIHR Health Technology Assessment programme	Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT
2019	European Network for Health Technology Assessment (EUnetHTA)	Point-of-care tests (POCT): D-dimer and troponin
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Volanesorsen (familial chylomicronaemia syndrome) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pomalidomide (multiple myeloma) - Addendum to Commission A19-50]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ivacaftor (cystic fibrosis, 18 years and older, with R117H mutation) - Benefit assessment according to §35a Social Code Book V]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ivacaftor (cystic fibrosis, 2 years and older, with gating mutations) - Benefit assessment according to §35a Social Code Book V]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ramucirumab (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ivacaftor (cystic fibrosis, 6 years and older, with G551D mutation) - Benefit assessment according to §35a Social Code Book V]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ivacaftor (combination with ivacaftor/tezacaftor, cystic fibrosis, 12 years and older, with F508del mutation, heterozygous) - Benefit assessment according to §35a Social Code Book V]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ivacaftor (cystic fibrosis, 6 years and older, with gating mutations) - Benefit assessment according to §35a Social Code Book V]
2019	Basque Office for Health Technology Assessment (OSTEBA)	[Closed vs open systems for the preparation and administration of cytostatic and other hazardous drugs (NIOSH Group 1): analysis of the scientific evidence, costs and organisational requirements]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ivacaftor (cystic fibrosis, from 12 to < 24 months, with gating mutations) - Benefit assessment according to §35a Social Code Book V]
2019	Basque Office for Health Technology Assessment (OSTEBA)	[Indications, utility and use of ultrasound in primary care]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ivacaftor (combination with ivacaftor/tezacaftor, cystic fibrosis, 12 years and older, with F508del mutation, homozygous) - Benefit assessment according to §35a Social Code Book V]
2019	Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)	[Use of incentive spirometry for the prevention of pulmonary complications following surgery]
2019	Basque Office for Health Technology Assessment (OSTEBA)	[Controlled and uncontrolled donation after circulatory death with regional normothermic or hypothermic perfusion based on extracorporeal membrane oxygenation for kidney and liver transplants]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Dupilumab (asthma) - Benefit assessment according to §35a Social Code Book V]
2019	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Clinical practice visits: a rapid review
2019	Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)	[Measurement of gastric residual volume during enteral feeding in patients hospitalized in the intensive care unit]
2019	Belgian Health Care Knowledge Centre (KCE)	Bariatric surgery : an HTA report on the efficacy, safety and cost-effectiveness
2019	Basque Office for Health Technology Assessment (OSTEBA)	[Methodological project: Synthesis of information in support of multicriteria decision analysis (MCDA) for decision making]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ibrutinib (new therapeutic indication, Waldenstroem macroglobulinaemia) - Benefit assessment according to §35a Social Code Book V]
2019	Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)	[Induction immunosuppressive therapy in patients undergoing heart transplantation]
2019	Belgian Health Care Knowledge Centre (KCE)	Cost-effectiveness analysis of HPV vaccination of boys in Belgium
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Dupilumab (atopic dermatitis in adolescents) - Benefit assessment according to §35a Social Code Book V]
2019	Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)	[Evaluation of the effectiveness and cost effectiveness of cardiac rehabilitation programs]
2019	Belgian Health Care Knowledge Centre (KCE)	The use of statins in the primary prevention of cardiovascular disease: an online tool for shared-decision making
2019	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: smoking cessation strategies]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Andexanet alfa (acute major bleeding) - Benefit assessment according to §35a Social Code Book V]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Dapagliflozin (type 2 diabetes mellitus) - Addendum to Commission A19-53]
2019	Belgian Health Care Knowledge Centre (KCE)	Proton beam therapy in adults
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Dapagliflozin/metformin (type 2 diabetes mellitus) - Addendum to Commission A19-52]
2019	Belgian Health Care Knowledge Centre (KCE)	Statins for the primary prevention of cardiovascular events
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Olaparib (breast cancer) - Addendum to Commission A19-57]
2019	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: considerations relating to the adoption of the learning health-care system approach, the reflective approach, and audit and feedback in the context of managing chronic diseases and multimorbid states]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Burosumab (X-linked hypophosphataemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision)]
2019	Institut national d'excellence en sante et en services sociaux (INESSS)	[Guidelines and standards: respiratory multiplex NAAT (8 or more targets)]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Elotuzumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Atezolizumab (NSCLC, combination chemotherapy with paclitaxel) - Benefit assessment according to §35a Social Code Book V]
2019	NIHR Health Technology Assessment programme	Goal-oriented cognitive rehabilitation for early-stage Alzheimer's and related dementias: the GREAT RCT
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Atezolizumab (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2019	NIHR Health Technology Assessment programme	Cognitive behavioural therapy for clozapine-resistant schizophrenia: the FOCUS RCT
2019	NIHR Health Services and Delivery Research programme	Developing a reporting guideline to improve meta-ethnography in health research: the eMERGe mixed-methods study
2019	NIHR Health Services and Delivery Research programme	Innovation to enhance health in care homes and evaluation of tools for measuring outcomes of care: rapid evidence synthesis
2019	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: use of rifapentine in the treatment of latent tuberculosis infection]
2019	Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS)	[Identification of psychosocial practices and interventions that support the adaptation and rehabilitation of adults with Prader-Willi Syndrome]
2019	NIHR Health Services and Delivery Research programme	Digital and online symptom checkers and assessment services for urgent care to inform a new digital platform: a systematic review
2019	NIHR Health Services and Delivery Research programme	Improving care for women and girls who have undergone female genital mutilation/cutting: qualitative systematic reviews
2019	NIHR Health Services and Delivery Research programme	Multicomponent hospital-led interventions to reduce hospital stay for older adults following elective surgery: a systematic review
2019	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: use of extracorporeal membrane oxygenation (ECMO) in adults in Quebec]
2019	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Charity and corporate boxing: harm mitigation
2019	Health Information and Quality Authority (HIQA)	Health technology assessment of C-reactive protein point-of-care testing to guide antibiotic prescribing for acute respiratory tract infections in primary care settings
2019	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: use of linear accelerators with on-board magnetic resonance imaging (MRI) for real-time MRI-guided radiation therapy treatments]
2019	Health Information and Quality Authority (HIQA)	Health technology assessment of a PrEP programme for populations at substantial risk of sexual acquisition of HIV